Rocket Pharmaceuticals, Inc. (RCKT)
Automate Your Wheel Strategy on RCKT
With Tiblio's Option Bot, you can configure your own wheel strategy including RCKT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RCKT
- Rev/Share 0.0827
- Book/Share 3.1905
- PB 1.1691
- Debt/Equity 0.0711
- CurrentRatio 6.3862
- ROIC -0.7035
- MktCap 402481920.0
- FreeCF/Share -1.8565
- PFCF -1.9528
- PE -1.6094
- Debt/Assets 0.0599
- DivYield 0
- ROE -0.66
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | RCKT | BofA Securities | Neutral | Buy | -- | $10 | Aug. 20, 2025 |
| Downgrade | RCKT | BofA Securities | Buy | Neutral | -- | $4 | July 25, 2025 |
| Downgrade | RCKT | Evercore ISI | Outperform | In-line | -- | $5 | May 30, 2025 |
| Downgrade | RCKT | Jefferies | Buy | Hold | -- | $2.5 | May 28, 2025 |
| Downgrade | RCKT | Leerink Partners | Outperform | Market Perform | -- | $8 | May 28, 2025 |
| Downgrade | RCKT | Morgan Stanley | Overweight | Equal Weight | -- | $7 | May 28, 2025 |
| Downgrade | RCKT | Goldman | Neutral | Sell | -- | $2 | May 28, 2025 |
| Downgrade | RCKT | JP Morgan | Overweight | Neutral | -- | -- | May 28, 2025 |
| Downgrade | RCKT | Needham | Buy | Hold | -- | -- | May 27, 2025 |
| Downgrade | RCKT | TD Cowen | Buy | Hold | -- | -- | May 27, 2025 |
News
RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study
Published: August 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Rocket Pharmaceuticals' shares soar as the FDA lifts its clinical hold on the pivotal Danon disease gene therapy study.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT) - August 11, 2025 Deadline to Join - Contact The Gross Law Firm
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). Shareholders who purchased shares of RCKT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
RCKT Deadline: RCKT Investors with Losses in Excess of $100K Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit
Published: August 10, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between September 17, 2024 and May 26, 2025, both dates inclusive (the "Class Period"), of the important August 11, 2025 lead plaintiff deadline. So what: If you purchased Rocket Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: August 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (“Rocket” or “the Company”) (NASDAQ: RCKT) and certain of its officers.
Read More
RCKT DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 11 Deadline in Securities Class Action – RCKT
Published: August 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between September 17, 2024 and May 26, 2025, both dates inclusive (the “Class Period”), of the important August 11, 2025 lead plaintiff deadline.
Read More
DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025
Published: August 08, 2025 by: PRNewsWire
Sentiment: Neutral
PHILADELPHIA , Aug. 8, 2025 /PRNewswire/ -- Berger Montague PC , a leading Philadelphia-based law firm representing investors, announces that a securities class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket Pharmaceuticals" or the "Company") on behalf of investors who suffered losses due to alleged material misstatements and omissions. If you purchased Rocket Pharmaceuticals stock during the period from September 17, 202 4 to May 26, 2025 (the "Class Period"), you may be entitled to compensation.
Read More
Deadline Soon: Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
Published: August 08, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming August 11, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT) securities between September 17, 2024 and May 26, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO LOST MONEY ON ROCKET PHARMACEUTICALS, INC. (RCKT), CLICK HERE TO PAR.
Read More
RCKT DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important August 11 Deadline in Securities Class Action – RCKT
Published: August 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between September 17, 2024 and May 26, 2025, both dates inclusive (the “Class Period”), of the important August 11, 2025 lead plaintiff deadline.
Read More
Deadline Alert: Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: August 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming August 11, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT) securities between September 17, 2024 and May 26, 2025, inclusive (the “Class Period”).
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT
Published: August 06, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 6, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
DEADLINE APPROACHING: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Inquire About a Securities Fraud Class Action by August 11, 2025
Published: August 05, 2025 by: PRNewsWire
Sentiment: Neutral
PHILADELPHIA , Aug. 5, 2025 /PRNewswire/ -- Berger Montague PC , a leading Philadelphia-based law firm representing investors, announces that a securities class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket Pharmaceuticals" or the "Company") on behalf of investors who suffered losses due to alleged material misstatements and omissions. If you purchased Rocket Pharmaceuticals stock during the period from September 17, 202 4 to May 26, 2025 (the "Class Period"), you may be entitled to compensation.
Read More
RCKT Deadline: RCKT Investors with Losses in Excess of $100K Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit
Published: August 05, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 5, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between September 17, 2024 and May 26, 2025, both dates inclusive (the "Class Period"), of the important August 11, 2025 lead plaintiff deadline. So what: If you purchased Rocket Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: August 05, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Aug. 5, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT). IF YOU SUFFERED A LOSS ON YOUR ROCKET INVESTMENTS, CLICK HERE BEFORE AUGUST 11, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?
Read More
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals
Published: August 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT
Published: August 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy Trial – Hagens Berman
Published: August 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
RCKT Investors with Losses Encouraged to Contact Hagens Berman Before Aug. 11th Deadline RCKT Investors with Losses Encouraged to Contact Hagens Berman Before Aug. 11th Deadline
Read More
Rocket Pharmaceuticals, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 11, 2025 Deadline to file Lead Plaintiff Motion.
Published: August 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
Investors can contact the law firm at no cost to learn more about recovering their losses
Read More
Deadline Alert: Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: August 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming August 11, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT) securities between September 17, 2024 and May 26, 2025, inclusive (the “Class Period”).
Read More
RCKT 10-DAY DEADLINE ALERT: FDA Clinical Hold on RP-A501 Trial Triggers Rocket Pharmaceuticals (RCKT) Stock Plunge and Class Action – Hagens Berman
Published: August 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- When, on May 27, 2025, Rocket Pharmaceuticals (NASDAQ: RCKT) revealed that the FDA put a clinical hold on its Phase 2 pivotal trial for RP-A501, an experimental therapy intended to treat patients with a rare gene disorder called Danon disease, investors in the company's shares saw their investment crash over 60% that day.
Read More
RCKT DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 11 Deadline in Securities Class Action – RCKT
Published: July 31, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between September 17, 2024 and May 26, 2025, both dates inclusive (the “Class Period”), of the important August 11, 2025 lead plaintiff deadline.
Read More
Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: July 31, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , July 31, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) have opportunity to lead the securities fraud class action lawsuit.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT
Published: July 31, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 31, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: July 30, 2025 by: PRNewsWire
Sentiment: Neutral
BENSALEM, Pa. , July 30, 2025 /PRNewswire/ -- The Law Offices of Howard G.
Read More
RCKT DEADLINE REMINDER: Berger Montague Reminds Rocket Pharmaceuticals (NASDAQ: RCKT) Investors of Important Class Action Lawsuit Deadline
Published: July 29, 2025 by: PRNewsWire
Sentiment: Neutral
PHILADELPHIA , July 29, 2025 /PRNewswire/ -- Berger Montague PC , a Philadelphia-based law firm focused on investor protection, is investigating claims against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket Pharmaceuticals" or the "Company") for potential violations of federal securities laws. A class action has been filed over allegations that the Company concealed safety concerns tied to its RP-A501 trial, leading to steep investor losses.
Read More
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals
Published: July 29, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Rocket Pharmaceuticals between February 27, 2025 and May 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , July 29, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rocket Pharmaceuticals, …
Read More
FDA Clinical Hold on RP-A501 Trial Triggers Rocket Pharmaceuticals (RCKT) Stock Plunge and Class Action – Hagens Berman
Published: July 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, July 28, 2025 (GLOBE NEWSWIRE) -- When, on May 27, 2025, Rocket Pharmaceuticals (NASDAQ: RCKT) revealed that the FDA put a clinical hold on its Phase 2 pivotal trial for RP-A501, an experimental therapy intended to treat patients with a rare gene disorder called Danon disease, investors in the company's shares saw their investment crash over 60% that day.
Read More
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT
Published: July 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between September 17, 2024 and May 26, 2025, both dates inclusive (the “Class Period”), of the important August 11, 2025 lead plaintiff deadline.
Read More
DEADLINE ALERT: Holzer & Holzer, LLC Reminds Investors of August 11, 2025 Lead Plaintiff Deadline in the Rocket Pharmaceuticals, Inc. (RCKT) Class Action – Investors With Significant Losses Encouraged to Contact the Firm
Published: July 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, July 28, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed Rocket Pharmaceuticals, Inc. (“Rocket Pharmaceuticals” or the “Company”) (NASDAQ: RCKT). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to adequately disclose that Rocket Pharmaceuticals knew Serious Adverse Events (SAEs), including death of participants enrolled in the study, were a risk.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT
Published: July 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
About Rocket Pharmaceuticals, Inc. (RCKT)
- IPO Date 2015-02-18
- Website https://rocketpharma.com
- Industry Biotechnology
- CEO Gaurav D. Shah
- Employees 299